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Volume 57, Number 5S Abstracts 65Ssuccess rate was 98.3%. The median follow-up duration was
51 months.
Overall, limb loss at 2 years was 8.9% (n ¼ 10), but
10.2% in patients who had smoked (9 of 88) vs 4.2%
in those who had not (1 of 24). Compared with the latter,
risk-adjusted odds ratios were 3.3 (P ¼ .04), 2.8 (P ¼ .05),
and 1.6 (P ¼ .1) for those whose timing of smoking cessa-
tion was categorized as current smoker, quit just after inter-
vention, and quit 3 months preoperatively.
Occurrence of reintervention at 2 years was 22.3% (n ¼
25) overall, but 25% in patients who had smoked (22 of
88) vs 12.5% in those who had not (3 of 24). Compared
with the latter, risk-adjusted odds ratios were 4.3 (P ¼
.01), 2.3 (P ¼ .03), and 1.2 (P ¼ .1) for those whose
timing of smoking cessation was categorized as above.
Conclusions: Direct effects of smoking on peripheral
arterial reactivity are considered to be responsible for
premature failure after intraluminal treatment of CLI in
young patients. Smoking cessation is presumed to be bene-
ﬁcial before endovascular treatment.
Risks of limb loss and reintervention after intervention
are increased by smoking and mitigated gradually by pre-
operative cessation.
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Objectives: Patients with severe CKD were excluded
from the SVS objective performance goals (OPG) deriva-
tion cohort due to established poor surgical outcomes in
this group. We examine the impact of diminished creati-
nine clearance (CrCl) on the long-term outcomes of
peripheral endovascular interventions.
Methods: Retrospective review of prospectively col-
lected institutional outcomes data (2006-2012) included
calculation of CrCl and stratiﬁcation by chronic kidney
disease (CKD) class. Outcomes among those with mild
(class 1, 2) moderate (class 3), and severe (class 4, 5) CKD
were compared using SVSOPG outcomemetrics. Multivar-
iate models were developed to identify risk factors for poor
outcome and speciﬁcally assess the impact of CKD.
Results: 454 patients underwent treatment of 523
limbs for claudication (56%), rest pain (12%), or tissue
loss (32%). Over 77% of patients had abnormally low
CrCl, with moderate CKD noted in 37% and severe
CKD in 13%. Increasing CKD class was associated with
worse outcomes across all outcome metrics by crude
survival analysis. Following adjustment for all other risk
factors, the impact of severe CKD was independently asso-
ciated with reduced overall survival (HR, 2.69; 95% CI,
1.70-4.26; P < .001), amputation-free survival (HR,
3.15; 95% CI, 2.04-3.86; P < .001), limb salvage (HR,4.35; 95% CI, 1.50-12.33; P ¼ .006), major adverse
limb events (HR, 2.07; 95% CI, 1.02-4.20; P ¼ .04),
freedom from reintervention and amputation (HR, 1.82;
95% CI, 1.12-2.94; P ¼ .015) and freedom from reinter-
vention, amputation, and stenosis (HR, 1.58; 95% CI,
1.02-2.46; P ¼ .041).
Conclusions: Moderate and severe CKD are highly
prevalent among patients with PAD. While severe CKD
adversely affects long-term outcomes after ET as well as
surgical bypass, quantiﬁcation of the impact of reduced
CrCl on survival- and limb-based metrics may enhance
risk adjustment for comparative effectiveness research and
improve patient-centered clinical decision-making.
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Objectives: The objectives is to investigate the long-
term efﬁcacy of FP stenting with nitinol stents for CLI.
Methods: This study was a multicenter retrospective
study. From January 2004 to December 2011, 598 consec-
utive patients (865 limbs; mean age 74.4 6 10.3 years;
61.5% male) who underwent successful FP stenting with
self-expandable nitinol stents for de novo lesions, CLI
were retrospectively analyzed. Outcome measures were
primary patency (PP), secondary patency (SP), overall
survival (OS), amputation free survival (AFS), limb salvage
(LS), major adverse cardiovascular events (MACE; all-
cause death, myocardial infarction and stroke), MALE
(repeat revascularization for the limb or major amputation
[deﬁned as above-the-ankle amputation]). Restenosis was
deﬁned as >2.4 of peak systolic velocity ratio by duplex
or >50% stenosis by angiogram. Primary patency was
deﬁned as treated vessels without restenosis and repeat
revascularization. Secondary patency was deﬁned as target
vessels that become totally occluded and are reopened by
repeat revascularization.
Results: Sixty-six percent of the patients had diabetes,
and 39% were on hemodialysis. The mean follow-up period
was 19.1 6 17.2 months. PP was 77.0%, 59%, and 46.7%,
and SP was 93.9%, 87.9%, and 80.3% at 1, 3, and 5 years,
respectively. OS was 83.4%, 63.1%, and 49.6%, and AFS
was 78.5%, 59.9%, 46.7%, and LS was 93.3%, 90.8%,
90.8%, and freedom from MACE was 82.1%, 61.5%,
45.7%, and freedom from MALE was 77.9%, 71.9%,
48.8%, respectively. Onmultivariate analysis by Cox propor-
tional hazard ratio, female gender (hazard ratio [HR], 1.4;
P ¼ .048), body mass index (HR, 1.05; P ¼ .04), cilostazol
administration (HR, 0.63; P ¼ .005), and TASC II class
C/D (HR, 1.67; P¼ .007) were the independent predictors
of primary patency after successful FP stenting.
